Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Short Interest Update

Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) was the recipient of a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 13,190,000 shares, a growth of 6.1% from the March 31st total of 12,430,000 shares. Based on an average daily trading volume, of 849,900 shares, the short-interest ratio is currently 15.5 days.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and issued a $4.00 price objective on shares of Citius Pharmaceuticals in a report on Wednesday, February 14th.

Citius Pharmaceuticals Stock Performance

NASDAQ:CTXR opened at $0.73 on Thursday. The stock’s 50 day moving average price is $0.79 and its 200 day moving average price is $0.76. Citius Pharmaceuticals has a 52 week low of $0.60 and a 52 week high of $1.56. The company has a market capitalization of $115.55 million, a P/E ratio of -2.79 and a beta of 1.45.

Citius Pharmaceuticals (NASDAQ:CTXR) last released its quarterly earnings data on Wednesday, February 14th. The company reported ($0.06) EPS for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.19). As a group, sell-side analysts forecast that Citius Pharmaceuticals will post -0.21 earnings per share for the current fiscal year.

Institutional Trading of Citius Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. BNP Paribas Financial Markets raised its holdings in Citius Pharmaceuticals by 88.5% in the 1st quarter. BNP Paribas Financial Markets now owns 69,615 shares of the company’s stock worth $62,000 after acquiring an additional 32,686 shares during the period. SG Americas Securities LLC bought a new position in shares of Citius Pharmaceuticals in the third quarter worth about $39,000. Allspring Global Investments Holdings LLC acquired a new position in shares of Citius Pharmaceuticals during the 3rd quarter worth about $76,000. Finally, Wealth Advisory Solutions LLC acquired a new position in shares of Citius Pharmaceuticals during the 1st quarter worth about $135,000. 16.88% of the stock is currently owned by institutional investors and hedge funds.

Citius Pharmaceuticals Company Profile

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.